<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2341-4545</journal-id>
<journal-title><![CDATA[GE-Portuguese Journal of Gastroenterology]]></journal-title>
<abbrev-journal-title><![CDATA[GE Port J Gastroenterol]]></abbrev-journal-title>
<issn>2341-4545</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Gastrenterologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2341-45452025000200017</article-id>
<article-id pub-id-type="doi">10.1159/000540338</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Early-Stage Colon Cancer Surveillance: Pattern and Timing of Recurrence and the Role of 5-Year Surveillance]]></article-title>
<article-title xml:lang="pt"><![CDATA[Vigilância do cancro do cólon em estadios iniciais: padrão de recorrência e o papel da vigilância até aos 5 anos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[Paula Ferreira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peyroteo]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baía]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[Maria João]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Videira]]></surname>
<given-names><![CDATA[José Flávio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Joaquim Abreu de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Português de Oncologia do Porto Surgical Oncology Department ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<volume>32</volume>
<numero>2</numero>
<fpage>17</fpage>
<lpage>25</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2341-45452025000200017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2341-45452025000200017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2341-45452025000200017&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Colorectal cancer is the third most prevalent cancer among both men and women with 80% of patients having localized disease enabling curative treatments. Given the low recurrence rate in early-stage disease, there is a growing interest in reviewing follow-up protocols. The aim of this study was to assess the frequency and timing of recurrence in early-stage colon cancer, as well as recurrence patterns.  Methods:  The data from all patients with colon adenocarcinoma consecutively treated with surgery at the Instituto Português de Oncologia do Porto, EPE, between January 2013 and December 2016, were retrospectively reviewed.  Results:  A total of 1,372 patients with colon cancer were submitted to surgery during the study period. From this group, 51.4% (n = 705) were early-stage colon cancers. Regarding the pathological stage, 3.5% were stage 0, 37.4%were stage I and 59.1% were stage II. The overall recurrence rate was 6.7%. When considering the group of patients without risk factors, the recurrence rate was 5.6%. The majority of recurrences occurred in the &#64257;rst 3 years of follow-up. The recurrence was diagnosed in the majority of patients through carcinoembryonic antigen elevation, followed by imaging exams. The presence of one or more risk factors (high nuclear grade, vascular invasion, extramural venous invasion, and perineural invasion) showed a statistically signi&#64257;cant association with recurrence rate.  Conclusion:  The recurrence rate was low in early-stage colon cancer, with the majority of recurrences occurring in the &#64257;rst 3 years. Our study results show that surveillance should be tailored according to individual risk factors.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  O cancro do cólon é o terceiro cancro mais prevalente tanto em mulheres como em homens. Cerca de 80% têm doença localizada ao diagnóstico, permitindo o tratamento curativo. Considerando a baixa taxa de recorrência em doentes com estadios iniciais, existe uma necessidade de rever os critérios e protocolos de vigilância. O objetivo do estudo é avaliar a frequência e padrão de recorrência em doentes com cancro do cólon em estadios iniciais.  Métodos:  Foram analisados retrospectivamente todos os doentes diagnosticados com adenocarcinoma do cólon tratados com cirurgia no Instituto Português de Oncologia do Porto, EPE, entre Janeiro de 2013 e Dezembro de 2016.  Resultados:  Durante este período, foram submetidos a cirurgia um total de 1,372 doentes com diagnóstico de cancro do cólon. Neste grupo, 51.4% (n = 705) têm tumores em estadio inicial ao diagnóstico. Considerando o estadio patológico, 3.5% são estadio 0, 37.4% são estadio I e 59.1% estadio II. A taxa de recorrência global foi de 6.7%. Quando analisamos o grupo sem fatores de mau prognóstico, a taxa de recorrência foi de 5.6%. A maioria dos casos de recorrência ocorreu nos primeiros 3 anos de vigilância, sendo que a recorrência foi diagnosticada, na maior parte dos casos, por aumento do CEA, seguido de exames de imagem. A presença de um ou mais fatores de risco (alto grau nuclear, invasão vascular, invasão venosa extramural e invasão perineural) mostrou uma associação estatisticamente signi&#64257;cativa com a taxa de recorrência.  Conclusão:  Em conclusão, a taxa de recorrência é baixa no cancro do cólon em estadios iniciais, com a maioria dos casos de recorrência a ocorrer nos primeiros 3 anos de vigilância. O presente estudo demonstra a importância da individualização da vigilância em função dos fatores de risco individuais.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Colon cancer]]></kwd>
<kwd lng="en"><![CDATA[Early stage]]></kwd>
<kwd lng="en"><![CDATA[Recurrence]]></kwd>
<kwd lng="en"><![CDATA[Surveillance]]></kwd>
<kwd lng="pt"><![CDATA[Cancro do cólon]]></kwd>
<kwd lng="pt"><![CDATA[Estadio inicial]]></kwd>
<kwd lng="pt"><![CDATA[Recorrência]]></kwd>
<kwd lng="pt"><![CDATA[Vigilância]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewandowska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rudzki]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lewandowski]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stryjkowska-Góra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rudzki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for the diagnosis of colorectal cancer]]></article-title>
<source><![CDATA[Cancer Control]]></source>
<year>2022</year>
<volume>29</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of surveillance imaging and endoscopy in colorectal cancer follow-up: quality over quantity?]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2019</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-68</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wille-Jorgensen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Syk]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Smedh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Laurberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2018</year>
<volume>319</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2095-103</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Francescatti]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Van Loon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between intensity of posttreatment surveillance testing and detection of recurrence in patients with colorectal cancer]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2018</year>
<volume>319</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2104-15</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Argilés]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tabernero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Labianca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hochhauser]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Iveson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2020</year>
<volume>31</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1291-305</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Wagle]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics, 2023]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2023</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-48</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gately]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jalali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Semira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Faragher]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Croxford]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ananda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stage dependent recurrence patterns and postrecurrence outcomes in non-metastatic colon cancer]]></article-title>
<source><![CDATA[Acta Oncol]]></source>
<year>2021</year>
<volume>60</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1106-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Venook]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Hawary]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[NCCN clinical practice guidelines in oncology: colon cancer Version 3]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological features of stage I-III colorectal cancer recurrence over 5 years after radical surgery without receiving neoadjuvant therapy: evidence from a large sample study.]]></article-title>
<source><![CDATA[Front Surg]]></source>
<year>2021</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>American Society of Clinical Oncology, Cancer</collab>
<source><![CDATA[Colorectal cancer statistics]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Departamento da Qualidade na Saúde</collab>
<source><![CDATA[Rastreio Oportunístico do Cancro do Cólon e Reto]]></source>
<year>2014</year>
<publisher-name><![CDATA[Direção Geral da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>ARS Norte Portugal</collab>
<source><![CDATA[Monitorização do Programa do Rastreio do Cancro do Cólon e Reto]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mão de Ferro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Areia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dias Pereira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Should colorectal cancer screening in Portugal at the age of 45 years? A cost-utility analysis]]></article-title>
<source><![CDATA[GE Port J Gastroenterol]]></source>
<year>2021</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>311-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Temin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharara]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costas-Chavarri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early detection for colorectal cancer: ASCO resource-stratified guideline]]></article-title>
<source><![CDATA[J Glob Oncol]]></source>
<year>2019</year>
<volume>5</volume>
<page-range>1-22</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
